Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam ...
Modern JavaScript teams do not just need more vulnerability reports. They need dependency decisions that developers can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results